Cogent Biosciences (COGT) Income from Continuing Operations (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Income from Continuing Operations of 111204000.0 for Q1 2026, down 54.48% year-over-year from 244308732.83 in Q1 2025, and down 1.04% quarter-over-quarter from 110059000.0 in Q4 2025.
Powered by 
Analysis
Cogent Biosciences (COGT) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Income from Continuing Operations for 10 consecutive years, with 111204000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 54.48% year-over-year to 111204000.0; the TTM figure through Mar 2026 stood at 382528000.0 (down 41.15% YoY), while the FY2025 annual figure was 1080622000.0, down 126.83% from the prior year.
- Income from Continuing Operations slipped to 111204000.0 in Q1 2026 per COGT's latest filing, from 110059000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 35907000.0 in Q1 2022 and bottomed at 111204000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 66121176.47 across 5 years, with a median of 62752000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 243.33% — and 2023, when it soared 36.61%.
- Cogent Biosciences' Income from Continuing Operations stood at 39984000.0 in 2022, then slumped by 47.54% to 58994000.0 in 2023, then fell by 1.64% to 59959000.0 in 2024, then sank by 83.56% to 110059000.0 in 2025, then fell by 1.04% to 111204000.0 in 2026.
- Business Quant data shows COGT's Income from Continuing Operations at 111204000.0 in Q1 2026, 110059000.0 in Q4 2025, and 85218000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Cogent Biosciences | 5.95 Bn | 5.95 Bn | - | -96.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -96.39 Mn |
| Mar 31, 2026 | -97.21 Mn |
| Dec 31, 2025 | -95.31 Mn |
| Sep 30, 2025 | -80.93 Mn |
| Jun 30, 2025 | -73.52 Mn |
| Mar 31, 2025 | -71.98 Mn |
| Dec 31, 2024 | -69.88 Mn |
| Sep 30, 2024 | -70.64 Mn |
| Jun 30, 2024 | -58.99 Mn |
| Mar 31, 2024 | -58.35 Mn |
| Dec 31, 2023 | -54.36 Mn |
| Sep 30, 2023 | -55.38 Mn |
| Jun 30, 2023 | -44.34 Mn |
| Mar 31, 2023 | -40.97 Mn |
| Dec 31, 2022 | -41.64 Mn |
| Sep 30, 2022 | -35.32 Mn |
| Jun 30, 2022 | -35.58 Mn |
| Mar 31, 2022 | -31.31 Mn |
| Dec 31, 2021 | -25.53 Mn |
| Sep 30, 2021 | -19.70 Mn |